Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model

Blood

Volumn 118, Issue 13, 2011, Pages 3698-3707

  Van Helden, Pauline M ^a   Unterthurner, Sabine ^a   Hermann, Corinna ^a   Schuster, Maria ^a   Ahmad, Rafi U ^a   Schiviz, Alexandra N ^a   Weiller, Markus ^a   Antoine, Gerhard ^a   Turecek, Peter L ^a   Muchitsch, Eva M ^a   Schwarz, Hans Peter ^a   Reipert, Birgit M ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG RESPONSE; FEMALE; HEMOPHILIA A; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 80053366223     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-316521     Document Type: Article

References (50)

1. Mannucci PM, Tuddenham EG. The hemophiliasfrom royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779. (Pubitemid 32497033)
2. Collins PW, Bjorkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8(2):269-275.
3. Saenko EL, Pipe SW. Strategies towards a longer acting factor VIII. Haemophilia. 2006;12(suppl 3):42-51.
4. Sommer J, Sim D, Leong L, Hacket F, Subramanyam B, Haaning J. Preservation of activity and prolonged efficacy of rFVIII after site-specific modification with high molecular weight hydroxyethyl starch. Haemophilia. 2010;16(suppl 4):39.
5. Dumont JA, Kamphaus GD, Fraley C, et al. Factor VIII-Fc fusion protein shows extended half-life and hemostatic activity in hemophilia A dogs [Abstract]. Blood. 2009;114(11):545.
6. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301-305. (Pubitemid 34303674)
7. Fehr T, Bachmann MF, Bucher E, et al. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med. 1997;185(10):1785- 1792. (Pubitemid 27242200)
8. Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev. 2000;176:154-170.
9. Levin LG, Jarvis M, Powell J, Harrison JA, Reisner HM. Induction of human factor VIII inhibitors in rats 2: Fine mapping of rat anti-human rFVIII antibodies. Thromb Haemost. 1996;76(6):998-1003. (Pubitemid 27013642)
10. Reipert BM, Ahmad RU, Turecek PL, Schwarz HP. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost. 2000;84(5):826-832.
11. Littlewood JD, Barrowcliffe TW. The development and characterisation of antibodies to human factor VIII in haemophilic dogs. Thromb Haemost. 1987;57(3):314-321. (Pubitemid 18024532)
12. Andrews JL, Shirley PS, Iverson WO, et al. Evaluation of the duration of human factor VIII expression in nonhuman primates after systemic delivery of an adenoviral vector. Hum Gene Ther. 2002;13(11):1331-1336. (Pubitemid 35034512)
13. Sasgary M, Schuster M, Schwarz HP, Reipert BM, Antoine G, Ehrlich HJ. Transgenic non-human animals expressing human blood clotting factors. US 2009/0235369 A1, http://ip.com/pdf/patapp/US20090235369. Accessed July 27, 2011.
14. van Helden PM, Sasgary M, Unterthurner S, et al. immune tolerance to human factor VIII induced by liver-specific expression of a human factor VIII le [Abstract]. Blood. 2008;112(11):3387.
15. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol. 2003;21:139-176. (Pubitemid 37174529)
16. Von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol. 2010;11(1):14-20.
17. Ottesen JL, Nilsson P, Jami J, et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia. 1994;37(12):1178-1185. (Pubitemid 24356756)
18. Stewart TA, Hollingshead PG, Pitts SL, Chang R, Martin LE, Oakley H. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol Biol Med. 1989;6(4):275-281. (Pubitemid 20108304)
19. Hermeling S, Jiskoot W, Crommelin D, Bornaes C, Schellekens H. Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm Res. 2005;22(6):847-851. (Pubitemid 40898093)
20. Hermeling S, Aranha L, Damen JM, et al. Structural characterization and immunogenicity in wildtype and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res. 2005;22(12):1997-2006. (Pubitemid 41821578)
21. Smith HW, Wierda D. Preclinical immunogenicity testing for recombinant therapeutic proteins. J Immunotoxicol. 2005;2(4):203-210. (Pubitemid 41789903)
22. Bril WS, van Helden PM, Hausl C, et al. Tolerance to factor VIII in a transgenic mouse expressing human factor VIII cDNA carrying an Arg(593) to Cys substitution. Thromb Haemost. 2006;95(2):341-347.
23. Kellendonk C, Opherk C, Anlag K, Schutz G, Tronche F. Hepatocyte-specific expression of Cre recombinase. Genesis. 2000;26(2):151-153. (Pubitemid 30158105)
24. Bi L, Lawler AM, Antonarakis SE, et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995;10(1):119-121.
25. Müller S, Neusser M, Wienberg J. Towards unlimited colors for fluorescence in-situ hybridization (FISH). Chromosome Res. 2002;10(3):223-232. (Pubitemid 34553496)
26. Pinkel D, Landegent J, Collins C, et al. Fluorescence in situ hybridization with human chromosome- specific libraries: detection of trisomy 21 and translocations of chromosome 4. Proc Natl Acad Sci U S A. 1988;85(23):9138-9142. (Pubitemid 19001853)
27. Zalipsky S. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjug Chem. 1995;6(2):150-165.
28. Kemptner J, Marchetti-Deschmann M, Siekmann J, Turecek PL, Schwarz HP, Allmaier G. GEMMA and MALDI-TOF MS of reactive PEGs for pharmaceutical applications. J Pharm Biomed Anal. 2010;52(4):432-437.
29. Rottensteiner H, Turecek PL, Meijer AB, et al. The prolonged half-life of PEGylated and polysialylated FVIII in murine models might be caused by a reduced binding to the LRP1 receptor [abstract]. Hämostaseologie. 2008;(28):P-02A-03.
30. Monetti C, Rottensteiner H, Gritsch H, Weber A, Scheiflinger F, Turecek PL. Structural analysis of the recombinant therapeutic product rFVIII and its PEGylated variants using 2-D DIGE. Electrophoresis. 2011;32(11):1292-1301.
31. Fraunhofer W, Winter G. The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics. Eur J Pharm Biopharm. 2004;58(2):369-383. (Pubitemid 39037242)
32. Hausl C, Maier E, Schwarz HP, et al. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost. 2002;87(5):840-845. (Pubitemid 34516612)
33. Kasper CK, Aledort L, Aronson D, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34(2):612.
34. Hausl C, Ahmad RU, Sasgary M, et al. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood. 2005;106(10):3415-3422. (Pubitemid 41609176)
35. Baumgartner B, Jaki T, Wolfsegger MJ, et al. Optimization, refinement and reduction of murine in vivo experiments to assess therapeutic approaches for haemophilia A. Lab Anim. 2010;44(3):211-217.
36. Qadura M, Waters B, Burnett E, et al. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood. 2009;114(4):871-880.
37. Mueller DL. Mechanisms maintaining peripheral tolerance. Nat Immunol. 2010;11(1):21-27.
38. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11(1):7-13.
39. Clark AJ, Harold G, Yull FE. Mammalian cDNA and prokaryotic reporter sequences silence adjacent transgenes in transgenic mice. Nucleic Acids Res. 1997;25(5):1009-1014. (Pubitemid 27298270)
40. Brinster RL, Sandgren EP, Behringer RR, Palmiter RD. No simple solution for making transgenic mice. Cell. 1989;59(2):239-241.
41. Palmiter RD, Sandgren EP, Avarbock MR, Allen DD, Brinster RL. Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci U S A. 1991;88(2):478-482. (Pubitemid 21915488)
42. Liu K, Sandgren EP, Palmiter RD, Stein A. Rat growth hormone gene introns stimulate nucleosome alignment in vitro and in transgenic mice. Proc Natl Acad Sci U S A. 1995;92(17):7724-7728.
43. Bovenschen N, Mertens K, Hu L, Havekes LM, van Vlijmen BJ. LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood. 2005;106(3):906-912. (Pubitemid 41076432)
44. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem. 1988;263(13):6352-6362.
45. Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol. 1989;9(3):1233-1242. (Pubitemid 19071692)
46. Balagué C, Zhou J, Dai Y, et al. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood. 2000;95(3):820-828. (Pubitemid 30062702)
47. Garrick D, Fiering S, Martin DI, Whitelaw E. Repeat-induced gene silencing in mammals. Nat Genet. 1998;18(1):56-59. (Pubitemid 28027880)
48. Sabatino DE, Armstrong E, Edmonson S, et al. Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene. Blood. 2004;104(9):2767-2774. (Pubitemid 39434960)
49. Connelly S, Andrews JL, Gallo-Penn AM, Tagliavacca L, Kaufman RJ, Kaleko M. Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice. Thromb Haemost. 1999;81(2):234-239. (Pubitemid 29078309)
50. Mukhopadhyay S, Pluddemann A, Gordon S. Macrophage pattern recognition receptors in immunity, homeostasis and self-tolerance. Adv Exp Med Biol. 2009;653:1-14.